HDAC9 and non-small cell lung carcinoma: To verify our finding, we treated NSCLC cells (H1650, PC9 and HCC827) with Erastin and Vorinostat, a clinically-approved class I HDAC inhibitor, alone or in combination, which showed that the presence of Vorinostat significantly enhances the anti-proliferative effect of Erastin (Figure 2A).